Trial Profile

A Phase 1/2 Study of Vorinostat (Zolinza) in Combination With Gemtuzumab Ozogamicin (Mylotarg) and Azacitidine (Vidaza) in Patients 50 Years of Age and Older With Relapsed/Refractory Non-APL Acute Myeloid Leukemia (AML).

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 06 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vorinostat (Primary) ; Azacitidine; Azacitidine; Gemtuzumab ozogamicin
Indications Acute biphenotypic leukaemia; Acute myeloid leukaemia
Focus Adverse reactions

10 Dec 2013 Results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
02 May 2013 Planned End Date changed from 1 Jun 2011 to 1 Jul 2013 as reported by ClinicalTrials.gov.
01 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com